Who are Hydralazine and magnesium valproate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydralazine-and-magnesium-valproate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Hydralazine and magnesium valproate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydralazine and magnesium valproate (Hydralazine and magnesium valproate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: vasodilator + histone deacetylase inhibitor. Area: Oncology.

phase 3 Combination therapy: vasodilator + histone deacetylase inhibitor HDAC (histone deacetylase); vascular smooth muscle relaxation pathways Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Hydralazine and magnesium valproate (Hydralazine and magnesium valproate) — National Institute of Cancerología. This combination uses hydralazine as a vasodilator and magnesium valproate as a histone deacetylase inhibitor to modulate vascular function and epigenetic pathways in cancer treatment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydralazine and magnesium valproate TARGET	Hydralazine and magnesium valproate	National Institute of Cancerología	phase 3	Combination therapy: vasodilator + histone deacetylase inhibitor	HDAC (histone deacetylase); vascular smooth muscle relaxation pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: vasodilator + histone deacetylase inhibitor class)

National Institute of Cancerología · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydralazine and magnesium valproate — Competitive Intelligence Brief. https://druglandscape.com/ci/hydralazine-and-magnesium-valproate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab